Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Tucatinib for Leptomeningeal Metastasis
This phase 2 study in patients with HER2-positive breast cancer and leptomeningeal metastases showed that tucatinib, trastuzumab, and capecitabine achieved a median overall surviva
New Protocol: Trabectedin Olaparib Combo for Soft Tissue Sarcoma
This phase II randomized study in advanced soft tissue sarcoma patients found a marginal progression-free survival benefit with trabectedin plus olaparib compared to trabectedin al
New Drug: Setidegrasib for kRAS G12D Mutated Cancers
This phase 1 study demonstrated that setidegrasib, a first-in-class selective KRAS G12D-targeted protein degrader, has antitumor activity in patients with previously treated advanc
New Drug: Oral Paclitaxel for Metastatic Breast Cancer
In this multinational phase III trial, oral paclitaxel DHP107 demonstrated non-inferior progression-free survival compared to intravenous weekly paclitaxel in patients with HER2-ne
New Reference: Nivolumab for 1st Line Hodgkin Lymphoma
In this phase 3 trial of patients with advanced-stage classic Hodgkin’s lymphoma, nivolumab combined with AVD chemotherapy resulted in significantly improved progression-free sur
New Reference: Fixed-Duration Treatment of CLL
This phase 3 trial in untreated chronic lymphocytic leukemia patients showed that fixed-duration treatment with venetoclax combinations was noninferior to continuous ibrutinib in p
New Protocol: Durvalumab – Olaparib for Ovarina Cancer
This phase III DUO-O study in newly diagnosed advanced-stage ovarian cancer patients without tumor BRCA mutation showed that adding durvalumab plus olaparib to carboplatin/paclitax
New Indication: Datopotamab deruxtecan for Untreated Metastatic Triple-Negative Breast Cancer
This phase III trial demonstrated that datopotamab deruxtecan significantly improved progression-free and overall survival compared with chemotherapy in patients with previously un
New Protocol: Adjuvant Atezolizumab in dMMR Colon Cancer
In this phase 3 randomized trial, the addition of atezolizumab to mFOLFOX6 significantly improved 3-year disease-free survival compared to mFOLFOX6 alone in patients with resected
